Pre-calving Administration of a Rumensin® Controlled Release Capsule for the Prevention of Energy-Associated Disease
Keywords:metabolic disease, transition, nutritional management, Rumensin controlled release capsule, ketosis, displaced abomasum
Since most metabolic disease occurs in the first month of lactation, efforts in prevention have focused on the transition period (six weeks centered around calving). Previous research in Ontario has shown that, in addition to good nutritional management, administration of a Rumensin controlled release capsule (CRC) two to four weeks pre-calving may reduce the incidence of clinical ketosis and displaced abomasum post-calving. The objective of this study was to confirm previous findings of the Rumensin CRC in different herds, regions and years.